Asymchem(06821)

Search documents
凯莱英(002821) - H股公告:证券变动月报表


2025-08-04 10:00
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 002821 | 說明 | | A股(深圳證券交易所) | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 333,040,460 | RMB | | 1 RMB | | 333,040,460 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 333,040,460 | RMB | | 1 RMB | | 333,040,460 | 本月底法定/註冊股本總額: RMB 360,593,720 致:香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團(天津)股份有限公司 呈交日期: 2025年8月 ...
港股收盘 | 三大指数涨跌互现 恒瑞医药125亿美元大单引爆医药股
Xin Lang Cai Jing· 2025-07-28 08:44
Market Performance - The Hong Kong stock market showed mixed performance with the Hang Seng Index rising by 0.68% to 25,562.13 points, while the Tech Index fell by 0.24% to 5,664.02 points, and the National Enterprises Index increased by 0.29% to 9,177.15 points [2][3]. Hang Seng Index Movement - The Hang Seng Index reached a high of 25,660.54 points in the morning but maintained a volatile pattern before closing slightly higher [4]. Sector Performance - Insurance, pharmaceuticals, and brokerage stocks saw collective strength, while coal, shipping, and photovoltaic stocks experienced adjustments [5]. Insurance Sector Strength - Major insurance stocks like AIA Group (up 4.96%), China Pacific Insurance (up 3.91%), and Ping An Insurance (up 3.49%) saw significant gains due to a favorable assessment of life insurance reserve interest rates, which are expected to lower the new business liability costs for insurers [6][7]. Pharmaceutical Sector Boost - Pharmaceutical stocks surged, with companies like Fonda Holdings (up 10.39%), Zhaoyan New Drug (up 6.76%), and Via Biotechnology (up 5.45%) benefiting from overseas licensing deals, including a notable $12.5 billion collaboration between Hengrui Medicine and GlaxoSmithKline [8][9]. Brokerage Sector Gains - Brokerage stocks such as Guotai Junan International (up 9.45%), Shenwan Hongyuan Hong Kong (up 7.32%), and Xingzheng International (up 5.08%) experienced strong performance, likely influenced by the upcoming implementation of the Stablecoin Regulation in Hong Kong [11][13]. Weakness in Cyclical Stocks - Coal, shipping, and photovoltaic stocks faced declines, with companies like Feishang Non-Ferrous Coal (down 15.28%) and COSCO Shipping Ports (down 10.99%) leading the downturn due to falling commodity prices in the futures market [14][18]. Individual Stock Movements - Xuanwu Cloud saw a significant increase of 28% following a strategic partnership with LG Uplus, while Zhejiang United Investment surged by 116.67% on expectations of turning a profit by April 2025 [23][24].
港股创新药50ETF(513780)午后拉升2%,凯莱英涨超10%!第十一批药品集采工作已启动!
Jin Rong Jie· 2025-07-24 07:14
Group 1 - The core viewpoint of the articles highlights the active performance of innovative drug stocks in the Hong Kong market, with the Hong Kong Innovative Drug 50 ETF (513780) rising over 87% year-to-date and experiencing significant net inflows since June [1][2] - Key individual stocks such as Kailaiying, CanSino Biologics, and others have shown substantial gains, indicating strong investor interest and confidence in the sector [1] - The National Healthcare Security Administration has initiated the 11th batch of centralized procurement, optimizing selection rules to ensure fair pricing and cost coverage for selected enterprises, which may positively impact the innovative drug market [1][2] Group 2 - Guosen Securities continues to recommend the innovative drug sector, citing improvements in both domestic and overseas markets, with recent adjustments to the medical insurance catalog providing economic support for innovative drug development [2] - The top ten constituents of the CSI Hong Kong Stock Connect Innovative Drug Index account for 69.16% of the index, including high-quality A-share companies involved in drug research and development [2] - The innovative drug sector is positioned at a new historical starting point, with domestic companies enhancing competitiveness and expanding overseas, supported by rapid revenue growth and favorable policies [2]
港股异动 | CRO概念股早盘走强 海外CRO企业二季度业绩超预期 机构称板块有望迎来戴维斯双击
智通财经网· 2025-07-23 03:19
Group 1 - CRO concept stocks experienced a strong performance in early trading, with notable gains from companies such as Fonda Holdings (+14.49%), Kanglong Chemical (+7.9%), and King’s Ray Biotechnology (+7.17%) [1] - Medpace, an overseas CRO company, saw its stock price jump over 44% at the opening, reaching a peak increase of 62.3% before closing with a nearly 54.7% rise, marking its highest closing record and the largest single-day increase since its listing nearly nine years ago [1] - Medpace's Q2 financial report indicated a revenue and EBITDA growth of over 10% year-on-year, exceeding analyst expectations by more than 11%, and the company raised its revenue and profit guidance for the year by at least 11% [1] Group 2 - Zhongtai Securities reported that WuXi AppTec and Boteng Co. released mid-year performance forecasts, with WuXi AppTec's adjusted net profit for the first half of 2025 expected to be approximately 6.31 billion yuan, reflecting a 44% year-on-year increase [2] - The CRO and CDMO sectors are anticipated to gradually recover due to multiple factors, including the onset of overseas interest rate cuts in Q4 2024, improved pessimistic expectations from geopolitical negotiations in Q2 2025, and the implementation of major domestic innovative drug projects and policies since 2025 [2] - The combination of recovering demand and a supply-side clean-up over the past three years is expected to lead to a "Davis Double Play" in profitability and valuation for the sector, suggesting significant investment opportunities [2]
港股医药外包概念股集体走强,金斯瑞生物科技(01548.HK)涨超6%,凯莱英(06821.HK)涨超5%,药明康德(02359.HK)涨超2%,泰格医药(03347.HK)涨超1%。
news flash· 2025-07-22 01:58
Group 1 - The Hong Kong pharmaceutical outsourcing sector stocks experienced a collective surge, indicating positive market sentiment [1] - Kingsoft Biotech (01548.HK) rose over 6%, reflecting strong investor interest [1] - Kelaiying (06821.HK) increased by more than 5%, showcasing robust performance in the sector [1] - WuXi AppTec (02359.HK) saw a rise of over 2%, contributing to the overall strength of the industry [1] - Tigermed (03347.HK) gained more than 1%, further highlighting the upward trend in pharmaceutical outsourcing stocks [1]
凯莱英(002821) - 关于召开2025年第二次临时股东大会、2025年第三次A股类别股东大会及2025年第三次H股类别股东大会通知的公告


2025-07-21 09:45
证券代码:002821 证券简称:凯莱英 公告编号:2025-049 凯莱英医药集团(天津)股份有限公司 关于召开2025年第二次临时股东大会、2025年第三次A股 类别股东大会及2025年第三次H股类别股东大会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整, 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团(天津)股份有限公司(以下简称"公司")将于2025年8月 6日以现场和网络投票相结合的方式召开2025年第二次临时股东大会、2025年第 三次A股类别股东大会及2025年第三次H股类别股东大会。现将本次会议有关事项 公告如下: 一、召开会议的基本情况 1、股东大会届次:2025年第二次临时股东大会、2025年第三次A股类别股东 大会及2025年第三次H股类别股东大会 2、会议召集人:公司董事会 3、会议召开的合法、合规性:本次股东大会会议召开符合《中华人民共和 国公司法》、《深圳证券交易所股票上市规则》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的相关规定。 4、会议召开的时间: 现场会议召开时间:2025年8月6日下午14:00 网络投票时间:2025年8月6日 ...
凯莱英: 第四届监事会第五十二次会议决议公告
Zheng Quan Zhi Xing· 2025-07-18 10:14
Group 1 - The company held its 52nd meeting of the 4th Supervisory Board on July 18, 2025, via communication, with all three supervisors present, complying with relevant laws and regulations [1][2] - The Supervisory Board approved a resolution to amend the Articles of Association, proposing the dissolution of the Supervisory Board, with its powers transferred to the Audit Committee of the Board of Directors [1][2] - The resolution received unanimous support with 3 votes in favor, and it will be submitted for approval at the company's second extraordinary general meeting of shareholders in 2025 [2] Group 2 - The company will continue to adhere to existing laws and regulations regarding the Supervisory Board until the shareholders' meeting approves the proposed changes [2] - The company aims to maintain compliance in overseeing the legality and compliance of its operations, finances, and the performance of directors and senior management [2]
凯莱英(002821) - 《凯莱英医药集团(天津)股份有限公司年报信息披露重大差错责任追究制度》


2025-07-18 09:46
凯莱英医药集团(天津)股份有限公司 年报信息披露重大差错责任追究制度 (2025 年 7 月修订) 凯莱英医药集团(天津)股份有限公司 年报信息披露重大差错责任追究制度 第一条 为了提高凯莱英医药集团(天津)股份有限公司(以下简称"公 司")的规范运作水平,增强信息披露的真实性、准确性、完整性和及时性, 提高年报信息披露的质量和透明度,根据《中华人民共和国公司法》(以下简称 "《公司法》"、《中华人民共和国证券法》(以下简称"《证券法》")、 《上市公司信息披露管理办法》、《深圳证券交易所股票上市规则》(以下简 称"《上市规则》")、《香港联合交易所有限公司证券上市规则》(以下简 称"《香港上市规则》")等有关法律法规及《凯莱英医药集团(天津)股份 有限公司章程》(以下简称"《公司章程》")和《凯莱英医药集团(天津)股 份有限公司信息披露管理办法》(以下简称"《信息披露管理办法》")的规 定,结合公司实际情况,制定本制度。 第二条 本制度所指责任追究是指年报信息披露工作中有关人员或单位因 不履行或者不正确履行职责、义务或其他原因而对公司造成重大经济损失或造成 不良社会影响时的责任追究与处理。 第三条 本制度所 ...
凯莱英(002821) - 《凯莱英医药集团(天津 )股份有限公司信息披露管理办法 》


2025-07-18 09:46
凯莱英医药集团(天津)股份有限公司 信息披露管理办法 (2025 年 7 月修订) | | | | 第一章 | 总 则 3 | | --- | --- | | 第二章 | 信息披露的基本原则 3 | | 第三章 | 公平信息披露 5 | | 第四章 | 信息披露的内容及标准 7 | | 第五章 | 信息披露的程序及管理 14 | | 第六章 | 信息披露的义务与责任 17 | | 第七章 | 信息披露方式 20 | | 第八章 | 信息保密 20 | | 第九章 | 其他 22 | | 第十章 | 附 则 22 | 第一章 总 则 第三条 公司董事会秘书负责公司信息披露,为公司信息披露的主要负责 人。 第四条 本办法对公司、公司股东、全体董事、高级管理人员、实际控制人 等相关信息披露义务人具有约束力。 第二章 信息披露的基本原则 第五条 信息披露是公司的持续责任,公司应依法、诚信履行持续信息披露 的义务。 第六条 公司及其他信息披露义务人应当真实、准确、完整、及时地披露信 息,不得有虚假记载、误导性陈述或者重大遗漏。 第七条 公司及其他信息披露义务人应当同时向所有投资者公开披露信息。 公司信息披露要体现公开、 ...
凯莱英(002821) - 《凯莱英医药集团(天津)股份有限公司规范与关联方资金往来的管理制度》


2025-07-18 09:46
凯莱英医药集团(天津)股份有限公司 规范与关联方资金往来的管理制度 (2025 年 7 月修订) 1 | | | 第二章 防范控股股东及其他关联方资金占用的原则 第四条 公司应与控股股东及其关联方的人员、资产、财务分开,机构、业 务独立,各自独立核算、独立承担责任和风险。 第五条 公司不得为董事、高级管理人员、控股股东及其他关联方提供资金 等财务资助。 | 第一章 | 总 则 3 | | --- | --- | | 第二章 | 防范控股股东及其他关联方资金占用的原则 3 | | 第三章 | 职责和措施 5 | | 第四章 | 责任追究及处罚 6 | | 第五章 | 附 则 7 | 第一章 总 则 第一条 为了建立防止控股股东及其他关联方占用凯莱英医药集团(天津) 股份有限公司(以下简称"公司")资金、侵占公司利益的长效机制,杜绝控股 股东及其他关联方占用公司资金行为的发生,保护投资者的合法权益,根据《中 华人民共和国公司法》(以下简称"《公司法》")、《上市公司监管指引第 8 号 ——上市公司资金往来、对外担保的监管要求》、《深圳证券交易所股票上市规则》 (以下简称"《上市规则》")、《深圳证券交易所上市公司 ...